ENDRA Life Sciences Receives Nasdaq Delisting Notice, Plans Appeal
Summary
ENDRA Life Sciences Inc. received a Nasdaq delisting notice for failing to meet the minimum stockholders' equity requirement and plans to request a hearing to appeal the decision.
Key Events
-
Delisting Notice Received
The company received a formal notification from Nasdaq Staff on April 20, 2026, stating non-compliance with the Minimum Stockholders' Equity Requirement (Rule 5550(b)(1)).
-
Non-Compliance with Equity Rule
Stockholders' equity of $2,260,120 as of December 31, 2025, fell below the required $2,500,000 minimum for continued listing.
-
Intent to Appeal
ENDRA Life Sciences Inc. intends to timely request a hearing before the Nasdaq Hearings Panel, which will temporarily stay the delisting action.
-
Ongoing Financial Distress
This notice follows the company's 2025 annual report, which disclosed a going concern warning, critically low cash, and high Nasdaq delisting risk.
Analysis
ENDRA Life Sciences Inc. has received a formal delisting notification from Nasdaq due to its stockholders' equity falling below the required minimum. This is a critical development, escalating the 'high Nasdaq delisting risk' previously disclosed in the company's 2025 annual report, which also included a going concern warning and critically low cash. While the company intends to appeal, which will temporarily stay the delisting, there is no assurance of regaining compliance. This event significantly increases the risk profile for investors and highlights the company's severe financial distress.
At the time of this filing, NDRA was trading at $6.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $2.90 to $11.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.